Physician profile
Scott Macleod
NPI 1831157379
$6,879.16
in general payments reported to CMS, 2019-2025
26 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $1,577 · 2021: $1,576 · 2022: $740 · 2023: $729 · 2024: $638 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,303.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,018.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $503.86 | 2019-2022 | |
| Lilly USA, LLC | $456.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $442.41 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.47 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $401.54 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Currax Pharmaceuticals LLC | $332.33 | 2019-2024 | Contrave, Nexletol, Nexlizet |
| Esperion Therapeutics, INC. | $295.56 | 2020-2023 | Nexletol |
| Abbvie INC. | $266.71 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.42 | 2019-2022 | |
| Pfizer INC. | $208.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $185.61 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $158.00 | 2019-2023 | Seglentis, Livalo |
| Abbott Laboratories | $155.74 | 2020-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $128.45 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $109.92 | 2020-2021 | |
| Glaxosmithkline, LLC. | $84.21 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.48 | 2019 | |
| Vanda Pharmaceuticals INC. | $27.37 | 2024 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $23.00 | 2019 | |
| Corcept Therapeutics | $19.54 | 2025 | Korlym |
| Viatris Specialty LLC | $18.53 | 2025 | Yupelri |
| Astellas Pharma US INC | $16.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Macleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.